Pricing, price revision, and clinical value of anticancer drugs in Japan: a retrospective observational study.

ABSTRACT:

Introduction

The high cost of anticancer drugs has raised concerns due to the financial burden on patients and pressure on healthcare systems. We examine the relation between pricing premiums, price revision, and clinical value for anticancer drugs approved in Japan.

Methods

We included anticancer drugs approved in Japan from 2013 to 2023. Differences in clinical value, as measured by the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS), among drugs receiving different premium proportions, were analyzed using the Mann-Whitney U test. Pearson correlation coefficients were calculated between treatment costs and clinical outcomes and value, including progression-free survival (PFS) gain, overall survival (OS) gain, objective response rate (O

SUBMITTER: He J 

PROVIDER: S-EPMC12668999 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature